STOCK Cebpbtm1.1Nord/Kctt

Status

Available to order

EMMA IDEM:04677
Citation informationRRID:IMSR_EM:04677 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameSTOCK Cebpbtm1.1Nord/Kctt
Alternative nameCebpbfl (ICER/129Sv/C57BL6)
Strain typeTargeted Mutant Strains : Conditional mutation
Allele/Transgene symbolCebpbtm1.1Nord
Gene/Transgene symbolCebpb

Information from provider

ProviderMagnus Nord
Provider affiliationDept of Medicine-Solna, Div f Respir Med, Karolinska Institutet
Additional ownerDr. Lukas Didon, Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, U.S.A.
Genetic informationFloxed Cebpb allele for conditional knockout. Neomycin expression cassette excised by mating with flp recombinase-expressing mice.
Phenotypic informationNo phenotype observed in the absence of cre recombinase.
Breeding historyAfter standard generation in C57BL/6 x 129/Sv background, ICR has been introduced.
ReferencesNone available
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreKarolinska Institutet, Stockholm, Sweden
Animals used for archivingheterozygous males, wild-type C57BL/6J females
Breeding at archiving centreNo breeding at archiving centre.
Stage of embryos2-cell

Disease and phenotype information

MGI phenotypes (gene matching)
  • hypoglycemia / MGI
  • extramedullary hematopoiesis / MGI
  • increased bone marrow cell number / MGI
  • decreased cell proliferation / MGI
  • abnormal mammary gland development / MGI
  • abnormal branching of the mammary ductal tree / MGI
  • enlarged spleen / MGI
  • enlarged lymph nodes / MGI
  • impaired ovarian folliculogenesis / MGI
  • absent corpus luteum / MGI
  • skin lesions / MGI
  • decreased body weight / MGI
  • abnormal osteoclast physiology / MGI
  • increased circulating triglyceride level / MGI
  • abnormal circulating free fatty acids level / MGI
  • increased circulating corticosterone level / MGI
  • decreased brown adipose tissue amount / MGI
  • impaired macrophage phagocytosis / MGI
  • abnormal humoral immune response / MGI
  • abnormal lactation / MGI
  • female infertility / MGI
  • decreased incidence of induced tumors / MGI
  • abnormal glucose homeostasis / MGI
  • premature death / MGI
  • abnormal lipid homeostasis / MGI
  • abnormal definitive hematopoiesis / MGI
  • no abnormal phenotype detected / MGI
  • abnormal lymph node cortex morphology / MGI
  • abnormal lymph node B cell domain morphology / MGI
  • abnormal lymph node secondary follicle morphology / MGI
  • abnormal lymph node T cell domain morphology / MGI
  • abnormal lymph node medulla morphology / MGI
  • abnormal spleen red pulp morphology / MGI
  • abnormal spleen white pulp morphology / MGI
  • abnormal mucosa-associated lymphoid tissue morphology / MGI
  • increased susceptibility to bacterial infection / MGI
  • abnormal innate immunity / MGI
  • abnormal cell-mediated immunity / MGI
  • abnormal plasma cell morphology / MGI
  • abnormal macrophage physiology / MGI
  • increased IgG level / MGI
  • granulomatous inflammation / MGI
  • decreased circulating triglyceride level / MGI
  • decreased circulating free fatty acid level / MGI
  • decreased glycogen catabolism rate / MGI
  • decreased circulating insulin level / MGI
  • enlarged submandibular lymph nodes / MGI
  • glomerulonephritis / MGI
  • increased insulin sensitivity / MGI
  • abnormal brown adipose tissue morphology / MGI
  • no phenotypic analysis / MGI
  • calcified muscle / MGI
  • decreased ovulation rate / MGI
  • impaired luteinization / MGI
  • impaired granulosa cell differentiation / MGI
  • abnormal gluconeogenesis / MGI
  • abnormal zygomatic arch morphology / MGI
  • decreased incidence of tumors by chemical induction / MGI
  • myositis / MGI
  • abnormal thoracic cage morphology / MGI
  • abnormal skeletal muscle mass / MGI
  • abnormal osteoclast morphology / MGI
  • decreased osteoclast cell number / MGI
  • increased bone resorption / MGI
  • abnormal osteoblast physiology / MGI
  • abnormal cell differentiation / MGI
  • abnormal clavicle morphology / MGI
  • decreased triglyceride level / MGI
  • abnormal enzyme/coenzyme level / MGI
  • reproductive system phenotype / MGI
  • increased susceptibility to fungal infection / MGI
  • decreased percent body fat/body weight / MGI
  • abnormal T-helper 1 physiology / MGI
  • abnormal T-helper 2 physiology / MGI
  • abnormal skeleton morphology / MGI
  • decreased liver regeneration / MGI
  • increased circulating glucose level / MGI
  • decreased susceptibility to type IV hypersensitivity reaction / MGI
  • hemosiderosis / MGI
  • abnormal adipose tissue physiology / MGI
  • decreased circulating leptin level / MGI
  • impaired lipolysis / MGI
  • abnormal osteoclast differentiation / MGI
  • enlarged mesenteric lymph nodes / MGI
  • abnormal spleen secondary B follicle morphology / MGI
  • increased circulating interleukin-6 level / MGI
  • decreased circulating interleukin-12 level / MGI
  • increased interleukin-12 secretion / MGI
  • decreased susceptibility to endotoxin shock / MGI
  • abnormal tumor necrosis factor level / MGI
  • increased physiological sensitivity to xenobiotic / MGI
  • decreased sensitivity to induced cell death / MGI
  • absent estrous cycle / MGI
  • decreased gonadal fat pad weight / MGI
  • decreased epididymal fat pad weight / MGI
  • decreased uterine fat pad weight / MGI
  • decreased trabecular bone thickness / MGI
  • increased trabecular bone thickness / MGI
  • decreased skeletal muscle fiber size / MGI
  • skeletal muscle fibrosis / MGI
  • abnormal mammary gland duct morphology / MGI
  • increased keratinocyte apoptosis / MGI
  • enlarged inguinal lymph nodes / MGI
  • enlarged axillary lymph nodes / MGI
  • abnormal mammary gland epithelium physiology / MGI
  • abnormal bone trabecula morphology / MGI
  • increased bone trabecula number / MGI
  • decreased bone trabecula number / MGI
  • increased bone volume / MGI
  • decreased bone volume / MGI
  • impaired adaptive thermogenesis / MGI
  • postnatal lethality, incomplete penetrance / MGI
  • neonatal lethality, incomplete penetrance / MGI
  • perinatal lethality, incomplete penetrance / MGI
  • prenatal lethality, incomplete penetrance / MGI
  • abnormal lymph node medullary cord morphology / MGI
  • renal glomerulus hypertrophy / MGI
  • expanded mesangial matrix / MGI
  • mesangial cell hyperplasia / MGI
  • decreased lipoprotein lipase activity / MGI
  • abnormal brown adipose tissue physiology / MGI
  • enhanced osteoblast differentiation / MGI
  • impaired skeletal muscle regeneration / MGI
  • increased bone ossification / MGI
  • decreased bone ossification / MGI
  • increased bone mineralization / MGI
  • decreased bone mineralization / MGI
  • increased muscle cell glucose uptake / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).